Emerging Noninvasive Biomarkers for Early Detection of Alzheimer's Disease

Archives of Medical Research

Volumn 43, Issue 8, 2012, Pages 663-666

  Guzmán Martínez, Leonardo ^a,b   Farías, Gonzalo A ^b   Maccioni, Ricardo B ^a,b  

^a UNIVERSITY OF CHILE   (Chile)

^b International Center for Biomedicine ICC   (Chile)

Author keywords

Alzheimer's disease; Biomarkers; Peripheral Marker; Platelet tau; Tau protein and peripheral blood

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; BLOOD; CEREBROSPINAL FLUID; EARLY DIAGNOSIS; MEDICAL LITERATURE; PROTEIN PHOSPHORYLATION; REVIEW;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BLOOD PLATELETS; EARLY DIAGNOSIS; HUMANS; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 84871652602     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.10.013     Document Type: Review

References (31)

1. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu Rev Neurosci 2001, 24:1121-1159.
2. Mandelkow E., von Bergen M., Biernat J., et al. Structural principles of tau and the paired helical filaments of Alzheimer's disease. Brain Pathol 2007, 17:83-90.
3. Garcia M.L., Cleveland D.W. Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. Curr Opin Cell Biol 2001, 13:41-48.
4. Maccioni R.B., Cambiazo V. Role of microtubule-associated proteins in the control of microtubule assembly. Physiol Rev 1995, 75:835-864.
5. Maccioni R.B., Munoz J.P., Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch Med Res 2001, 32:367-381.
6. Spillantini M.G., Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci 1998, 21:428-433.
7. Weaver C.L., Espinoza M., Kress Y., et al. Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging 2000, 21:719-727.
8. Mocanu M.M., Nissen A., Eckermann K., et al. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci 2008, 28:737-748.
9. Ferri C.P., Prince M., Brayne C., et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117.
10. Llibre Rodriguez J.J., Ferri C.P., Acosta D., et al. Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey. Lancet 2008, 372:464-474.
11. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiant 1907, 64:146-148.
12. Fukutani Y., Kobayashi K., Nakamura I., et al. Neurons, intracellular and extracellular neurofibrillary tangles in subdivisions of the hippocampal cortex in normal ageing and Alzheimer's disease. Neurosci Lett 1995, 200:57-60.
13. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34. 939-344.
14. Dubois B., Feldman H.H., Jacova C., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746.
15. Wiltfang J., Esselmann H., Bibl M., et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF Abeta 40 load. J Neurochem 2007, 101:1053-1059.
16. Neumann K., Farias G., Slachevsky A., et al. Human platelets tau: a potential peripheral marker for Alzheimer's disease. J Alzheimers Dis 2011, 25:103-109.
17. Farias G., Perez P., Slachevsky A., et al. Platelet tau pattern correlates with cognitive status in Alzheimer's disease. J Alzheimers Dis 2012, 31:65-69.
18. Lavados M., Farias G., Rothhammer F., et al. ApoE alleles and tau markers in patients with different levels of cognitive impairment. Arch Med Res 2005, 36:474-479.
19. Cummings J.L., Doody R., Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007, 69:1622-1634.
20. McKhann G.M. Changing concepts of Alzheimer disease. JAMA 2011, 305:2458-2459.
21. Maccioni R.B., Lavados M., Guillon M., et al. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects. Neurobiol Aging 2006, 27:237-244.
22. Maccioni R.B., Lavados M., Maccioni C.B., et al. Biological markers of Alzheimer's disease and mild cognitive impairment. Curr Alzheimer Res 2004, 1:307-314.
23. Lavados M., Guillon M., Mujica M.C., et al. Mild cognitive impairment and Alzheimer patients display different levels of redox-active CSF iron. J Alzheimers Dis 2008, 13:225-232.
24. Gustafson D.R., Skoog I., Rosengren L., et al. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 2007, 78:461-464.
25. Vanderstichele H., De Vreese K., Blennow K., et al. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med 2006, 44:1472-1480.
26. Rojo L., Sjoberg M.K., Hernandez P., et al. Roles of cholesterol and lipids in the etiopathogenesis of Alzheimer's disease. J Biomed Biotechnol 2006, 2006:73976.
27. Rojo L.E., Fernandez J.A., Maccioni A.A., et al. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 2008, 39:1-16.
28. Luchsinger J.A., Tang M.X., Miller J., et al. Relation of plasma homocysteine to plasma amyloid beta levels. Neurochem Res 2007, 32:775-781.
29. Ewers M., Buerger K., Teipel S.J., et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 2007, 69:2205-2212.
30. Lanni C., Racchi M., Mazzini G., et al. Conformationally altered p53: a novel Alzheimer's disease marker?. Mol Psychiatry 2008, 13:641-647.
31. Mayeux R., Saunders A.M., Shea S., et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med 1998, 338:506-511.